CandlesenseCandlesense
News/Companies/KLTO

KLTO News

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

KLTO

Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology...

August 18, 2025Funding
Read more →

Klotho Neurosciences Amends April 2022 Public Warrant to Reprice Exercise From $3.49 to $1.35 Between June 10–20, 2025, Before Reverting To $3.49

KLTO

June 11, 2025
Read more →

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 709.8%

KLTO

June 9, 2025
Read more →

Klotho Neurosciences (KLTO) Stock Surges Over 680%: What's Going On?

KLTO

Shares of Klotho Neurosciences skyrocketed over 500% after announcing promising new study findings. Its licensed therapy shows potential to reduce age-related degeneration and significantly increase healthy lifespan.

June 9, 2025
Read more →

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 700%

KLTO

June 9, 2025
Read more →

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 636.6%

KLTO

June 9, 2025
Read more →

US Stocks Mixed; Motorcar Parts of America Posts Upbeat Earnings

KLTO

June 9, 2025
Read more →

Klotho Neurosciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 417.1%

KLTO

June 9, 2025
Read more →

Klotho Neurosciences Says Gene Therapy Boosted Lifespan by 20% in Mice, Eyes Anti-Aging Breakthrough

KLTO

June 9, 2025
Read more →

Klotho Neurosciences Appeals Nasdaq Delisting Decision, Seeks to Maintain Compliance

KLTO

February 24, 2025
Read more →